illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. health care
  6. ›
  7. Glaxosmithkline Pharmaceuticals
Company logo

Glaxosmithkline Pharmaceuticals | Sustainability Performance

https://www.gsk.com/en-gb/

Indian subsidiary of GSK, focusing on pharmaceutical products and healthcare solutions.

1924

India

1,001 - 5,000 employees

Pharmaceuticals

$100M - 500M in revenue

$100M - 500M in profitability

Submit or report inaccurate dataDownload Company Insights

Sustainability Ranking & Industry Benchmark

#6385
Overall
#97
in India
#134
in Pharmaceuticals

Sustainability Maturity

​​0123456789​​%

Sustainability Intent

Available in
Scale package

Access
​​0123456789​​%

Industry Rank

232 out of 311

Overview
Governance
TargetsESG scores and Exclusions
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies


Company logo
RPG Life Sciences

India, Health Care, Pharmaceuticals


Company logo
Solara Active Pharma Sciences

India, Health Care, Pharmaceuticals


Company logo
Ipca Laboratories

India, Health Care, Pharmaceuticals

Market cap

369.5B $, 2026▲48.8% YoY

Revenue

37.5B $, 2025▼7.9% YoY

R&D intensity

0% 2025

Controversy level


Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
Powered by illuminem

Market cap

369.5B $, 2026▲48.8% YoY

Revenue

37.5B $, FY2025▼7.9% YoY

EBITDA

11.8B $, FY2025▼9.1% YoY

Operating margin

30% Industry: -33▼18.3% YoY

P/E ratio

45.2 Industry: 26▲43.1% YoY

Revenue & EBITDA

$37.5BFY2025 revenue

Total Annual
Revenue & EBITDA
($ B)

Annual revenue
EBITDA
3 year change
Powered by illuminem

Margin trends


Margin as % of revenue

Gross margin
Operating margin
Net margin

Powered by illuminem

Free cashflow

12.7B 2025▼56.5% YoY

Capex

247.0M 2025▲26.3% YoY

Debt/equity ratio

0.0 Industry: 0▼NaN% YoY

R&D intensity

0.0%FY2025

R&D as % of revenue

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Return on invested capital

47.0%FY2026

Return on invested capital (ROIC)
Industry benchmark

Powered by illuminem

Analyst revenue estimates & actuals


Analyst consensus vs actuals
($ B)

Actual revenue
Consensus estimates
Estimate only

32.5

▼ 4.5%

2023

34.5

▼ 0.3%

2024

37.5

▼ 3.3%

2025

48.6

2028

Powered by illuminem

Environmental policy coverage

Carbon reduction policy

Not available

Human rights policy

Available

Recycling policy

Available

Workplace health & safety policy

Available

22%
Independent Directors

5 out of 23 incl. management

Powered by illuminem

Overall score

63

Environment

76

Social

79

Governance

35

Exclusion screening

Adult content

Not available

Alcoholic

Not available

Animal testing

Available

Firearms

Not available

Tobacco

Not available

Gambling

Not available

Nuclear

Not available

Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

Available

Not committed to key sustainability initiatives

Sustainability employees


Total sustainability employees

11+


    Available in
    Scale package

    Access
  • Email

  • Email